Klacid Sr

Clarithromycin, the active ingredient in Klacid Sr, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, skin and soft‑tissue infections, and is used in Helicobacter pylori eradication regimens.

GNH USA supplies Klacid Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klacid Sr is a macrolide antibiotic used to treat a range of bacterial infections affecting the respiratory tract, skin and gastrointestinal system. - Community‑acquired pneumonia: eliminates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute exacerbations of chronic bronchitis: controls bacterial overgrowth and eases symptoms. - Skin and soft‑tissue infections: eradicates susceptible organisms and promotes wound healing. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of a multi‑drug regimen.

Clarithromycin may cause a range of adverse reactions, from mild to severe. Awareness of common and serious events helps guide monitoring.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, anaphylaxis. - QT interval prolongation: risk of cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile infection: severe colitis. - Arrhythmias: ventricular tachycardia or fibrillation. - Anaphylaxis: life‑threatening hypersensitivity.

Before prescribing Klacid Sr, clinicians should evaluate patient-specific factors and monitor for potential complications. - Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor cardiac status: avoid in patients with known QT prolongation. - Avoid in individuals with documented macrolide hypersensitivity. - Use caution during pregnancy and lactation: benefits must outweigh potential risks. - Review concomitant medications for interaction potential. - Store at below 25°C: keep in the original pack, protect from moisture.

Clarithromycin interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Cisapride and pimozide: risk of serious cardiac arrhythmias. - Simvastatin and lovastatin: increased risk of myopathy. - Ergot alkaloids: potential for ergotism. - Colchicine: heightened toxicity, especially in renal impairment. - Warfarin: enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - Oral contraceptives: possible reduction in efficacy. - Digoxin: increased serum concentrations. - Carbamazepine and phenytoin: reduced clarithromycin levels. - Rifampin: decreased clarithromycin exposure.